ROCKET PHARMACEUTICALS, INC. - 10-Q Filing

Rocket Pharmaceuticals, Inc. reports Q3 2025 financial results including research and development expenses and updates on debt facilities.

SEC EDGAR ·

Tickers: $RCKT

Read the full article at SEC EDGAR

More Regulatory news